Zacks: Brokerages Anticipate Beyondspring Inc (BYSI) to Post -$0.55 Earnings Per Share
Analysts predict that Beyondspring Inc (NASDAQ:BYSI) will announce earnings per share of ($0.55) for the current quarter, Zacks reports. Zero analysts have made estimates for Beyondspring’s earnings. Beyondspring reported earnings per share of ($0.68) during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.1%. The business is expected to report its next earnings report on Tuesday, April 2nd.
According to Zacks, analysts expect that Beyondspring will report full-year earnings of ($2.25) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($2.02) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Beyondspring.
Beyondspring (NASDAQ:BYSI) last issued its quarterly earnings results on Tuesday, October 23rd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.08.
A hedge fund recently raised its stake in Beyondspring stock. Tanaka Capital Management Inc. boosted its holdings in Beyondspring Inc (NASDAQ:BYSI) by 106.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 49,584 shares of the company’s stock after buying an additional 25,606 shares during the period. Beyondspring accounts for approximately 2.9% of Tanaka Capital Management Inc.’s holdings, making the stock its 11th biggest position. Tanaka Capital Management Inc. owned about 0.22% of Beyondspring worth $1,240,000 at the end of the most recent quarter. 1.37% of the stock is currently owned by hedge funds and other institutional investors.
BYSI stock traded up $0.52 during trading on Friday, reaching $24.11. The company’s stock had a trading volume of 16,826 shares, compared to its average volume of 9,101. Beyondspring has a 1 year low of $16.15 and a 1 year high of $34.00. The firm has a market capitalization of $529.26 million, a PE ratio of -5.48 and a beta of 1.33.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Read More: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.